Bavarian Nordic’s BLA for the liquid-frozen version of the MVA-BN for active immunization against smallpox has been accepted by the FDA and granted priority review. The agency is targeting completion of the review in six months rather than the standard 10 months. Priority review is granted to applications for medicines that would offer a significant improvement in the treatment, diagnosis, or prevention of serious conditions. If approved, MVA-BN would be the first and only approved non-replicati...